Market watch

Innovation in the preclinical antibiotic pipeline

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Analysis of CARB-X applications.


U.T, M.S. and C.Å. were partly supported by the Innovative Medicines Initiative Joint Undertaking DRIVE-AB grant number 115583; M.S. and C.Å. are partly funded by the Norwegian Research Council (grant number 234608); K.O. is supported by the Cooperative Agreement Number 6 IDSEP160030-02-01from the Biomedical Advanced Research and Development Authority (BARDA) and by an award from the Wellcome Trust. CARB-X is also supported by the National Institute of Allergy and Infectious Diseases. This article is solely the responsibility of the authors and does not necessarily represent the official views of The Assistant Secretary for Preparedness and Response, the National Institutes of Health, the Wellcome Trust, DRIVE-AB or the Innovative Medicines Initiative.

Author information



Corresponding author

Correspondence to Ursula Theuretzbacher.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Theuretzbacher, U., Savic, M., Årdal, C. et al. Innovation in the preclinical antibiotic pipeline. Nat Rev Drug Discov 16, 744–745 (2017).

Download citation

Further reading